Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

VYNE THERAPEUTICS INC.

(VYNE)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
01/19/2022 01/20/2022 01/21/2022 01/24/2022 01/25/2022 Date
0.66(c) 0.6441(c) 0.63(c) 0.6302(c) 0.6264(c) Last
1 599 621 1 602 896 1 335 092 1 240 389 612 173 Volume
-4.22% -2.41% -2.19% +0.03% -0.60% Change
More quotes
Estimated financial data (e) (USD)
Sales 2021 16,6 M - -
Net income 2021 -72,2 M - -
Net Debt 2021 - - -
P/E ratio 2021 -0,46x
Yield 2021 -
Sales 2022 7,58 M - -
Net income 2022 -44,9 M - -
Net Debt 2022 - - -
P/E ratio 2022 -0,82x
Yield 2022 -
Capitalization 33,5 M 33,5 M -
Capi. / Sales 2021 2,02x
Capi. / Sales 2022 4,42x
Nbr of Employees 106
Free-Float -
More Financials
Company
Vyne Therapeutics Inc. is a specialty pharmaceutical company. The Company is engaged in developing proprietary and differentiated therapies for the treatment of immuno-inflammatory conditions and rare skin diseases with high unmet medical need. The CompanyÔÇÖs proprietary pipeline FMX114, which is a potential treatment of mild-to-moderate atopic dermatitis in patients 12 years of age and older, and access to a... 
Sector
Pharmaceuticals
Calendar
03/03Earnings Release
More about the company
Ratings of VYNE Therapeutics Inc.
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
C-
More Ratings
All news about VYNE THERAPEUTICS INC.
01/19VYNE Therapeutics Completes Phase 1b Data for FMX114 for Atopic Dermatitis
MT
01/19VYNE THERAPEUTICS : Announces Phase 1b Data for FMX114 from Phase 1b/2a Trial for the Trea..
PU
01/19VYNE THERAPEUTICS INC. : Other Events, Financial Statements and Exhibits (form 8-K)
AQ
01/19VYNE Therapeutics Announces Phase 1b Data for FMX114 from Phase 1b/2a Trial for the Tre..
AQ
01/19VYNE Therapeutics Inc. Announces Phase 1B Data for Fmx114 from Phase 1B/2A Trial for th..
CI
01/14VYNE THERAPEUTICS : Unaudited Pro Forma Condensed Consolidated Financial Information - For..
PU
01/14VYNE THERAPEUTICS INC. Change in Directors or Principal Officers, Financial Statements..
AQ
01/14VYNE Therapeutics Inc. Announces Board Changes
CI
01/14Health Care Stocks Drop Premarket Friday
MT
01/13Health Care Stocks Losing More Ground as Biotechs Sputter in Late Trade
MT
01/13Wall Street Set for Narrow Gains; US Wholesale Prices Rise Less Than Expected in Decemb..
MT
01/13Thinking about buying stock in Adagio Therapeutics, Vyne Therapeutics, PetVivo, BTCS In..
PR
01/13Journey Medical Acquires Vyne Therapeutics' Molecule Stabilizing Technology Franchise
MT
01/13VYNE THERAPEUTICS : Divests Topical Minocycline Assets - Form 8-K
PU
01/13VYNE THERAPEUTICS INC. : Entry into a Material Definitive Agreement, Completion of Acquisi..
AQ
More news
News in other languages on VYNE THERAPEUTICS INC.
01/19VYNE Therapeutics achève les données de phase 1b sur le FMX114 pour la dermatite atopiq..
01/19VYNE Therapeutics Inc. annonce les données de l'essai de phase 1B/2A pour le Fmx114 dan..
01/14VYNE Therapeutics Inc. annonce des changements au conseil d'administration
01/14Les actions du secteur de la santé chutent vendredi en prémarché
01/13Les actions du secteur de la santé perdent encore du terrain alors que les biotechs vac..
More news
Analyst Recommendations on VYNE THERAPEUTICS INC.
More recommendations
Chart VYNE THERAPEUTICS INC.
Duration : Period :
VYNE Therapeutics Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends VYNE THERAPEUTICS INC.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 6
Last Close Price 0,63 $
Average target price 5,80 $
Spread / Average Target 826%
EPS Revisions
Managers and Directors
David Domzalski President, Chief Executive Officer & Director
Tyler Zeronda Chief Financial Officer & Treasurer
Iain A. Stuart Chief Scientific Officer
Sharon Barbari Independent Director
Steven L. Basta Independent Director
Sector and Competitors
1st jan.Capi. (M$)
VYNE THERAPEUTICS INC.-38.59%34
JOHNSON & JOHNSON-2.01%441 302
ROCHE HOLDING AG-8.68%304 745
PFIZER, INC.-11.02%294 900
ABBVIE INC.-1.71%235 287
ELI LILLY AND COMPANY-13.31%217 093